Rational design of inhibitors that bind to inactive kinase conformations (Q29617558)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

30 April 2017

author name string

Liu Y

series ordinal

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

30 April 2017

Gray NS

series ordinal

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

July 2006

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

30 April 2017

published in

Nature Chemical Biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

30 April 2017

volume

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

30 April 2017

issue

7

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

30 April 2017

page(s)

358-64

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

Exploiting structural principles to design cyclin-dependent kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Protein kinases--the major drug targets of the twenty-first century?

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Structural basis for selective inhibition of Src family kinases by PP1

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Structural basis of inhibitor selectivity in MAP kinases

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Crystal structure of the tyrosine kinase domain of the human insulin receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Imatinib: a selective tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Design and discovery of small molecules targeting raf-1 kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

Second-generation kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCHEMBIO799

7 January 2021

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1050699600

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16783341

PubMed publication ID

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017